PCN2: DARBEPOETIN ALFA 200 MCG EVERY 2 WEEKS (Q2W) AND EPOETIN ALFA 40,000 UNITS EVERY WEEK (QW) IN CHEMOTHERAPY-INDUCED ANEMIA PATIENTS RESULT IN SIMILAR INITIAL HEMOGLOBIN OUTCOMES  by Patton, J & Wallace, JF
228 Abstracts
(89%). Predictors of second treatment after biochemical
failure for RP included PSA at diagnosis (p < .0001), T
stage (p = .0062) and biopsy Gleason score (p = .0109).
Patients with a PSA > 20, T3 disease and Gleason 8–10
had a 4.5 fold, 3.6 fold and 3.5 fold increased risk of
second treatment as compared to patients with a PSA <
4, T1 disease, and Gleason 2–6, respectively. For XRT,
predictors of second treatment included biopsy Gleason
score (p < .0001) and PSA at diagnosis (p = .0057).
Patients with Gleason 8–10 and PSA > 20 had a 5.4 fold
and 6.5 fold increased risk of second treatment as com-
pared to patients with Gleason 2–6 and PSA < 4, respec-
tively. CONCLUSION: Second treatment timing and type
differs for RP and XRT patients who fail biochemically.
Pretreatment clinical factors can be used to determine
which patients are at highest risk for second treatment.
This has implications for initial treatment efﬁcacy.
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Darbepoetin alfa (Aranesp®, DA), a unique erythropoi-
etic molecule with 3-fold longer half-life than epoetin alfa
(EPO), is indicated for treatment of chemotherapy-
induced anemia (CIA). OBJECTIVE: To determine the
most common initial dosing regimens for DA and EPO in
clinical practice and evaluate their effectiveness after four
weeks of therapy. METHODS: In order to determine
which initial regimens are most commonly used in prac-
tice as well as their effectiveness, we conducted a chart
review within Tennessee Oncology. Tennessee Oncology,
a major provider of cancer care in the Nashville area, 
has collected extensive data on EPO and DA use as part
of their quality assurance process. DA patients switched
from EPO were not eligible for the analysis. Mean hemo-
globin changes were not adjusted for transfusions.
RESULTS: Of 408 patients treated with an erythropoetic
agent, 196 received DA and 212 received EPO. The
majority of EPO patients (86.3%) had an initial dosing
schedule of 40,000 U QW (EPO40KQW). The majority
of DA patients received a ﬁxed dose. Of 196 DA patients,
97 (49.5%) received 100 mcg QW (DA100QW) and 70
(35.7%) received 200 mcg Q2W (DA200Q2W). Hemo-
globin (hgb) values were collected at baseline and begin-
ning of week 5. Mean baseline hgb (g/dL) [95% CL] for
the DA100QW, DA200Q2W and EPO40KQW groups
were 10.2 [±0.15], 9.9 [±0.18], and 9.7 [±0.14], respec-
tively. Mean changes in hgb (g/dL) [95%CL] after 4
weeks of therapy for the DA100QW, DA200Q2W, and
EPO40KQW group were 0.9 [±0.24], 1.1 [±0.29], and
0.8 [±0.22], respectively. The median for each group was
very similar to the corresponding mean. CONCLU-
SIONS: These results establish that 200mcg Q2W DA
maintained dose efﬁciency when compared to 100mcg
QW and was at least as effective as 40,000 U QW of EPO
after 4 weeks therapy in patients with CIA.
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OBJECTIVES: In the era of restricted ﬁnancial resources
for health care different strategies are developed to 
optimize patient outcome, but all of them need a valid
outcome measurement. One of such concepts for surgical
patients is the McPeek-Score which was evaluated in three
trials. METHODS: The discontinuous McPeek-Score
gives 1 point for a patient who died in the operation
theatre, 2 for one who died in hospital postoperatively, 4
or 5 for a patient discharged alive with great or moder-
ate amount of ICU care, 7, 8 or 9 points for a routine
recovery with long, average or short postoperative 
hospitalization, respectively. The postoperative recovery
index of McPeek was used in 699 patients in 3 trials.
Patients in trial 1 had elective, colorectal cancer surgery,
in trial 2 oncological, endocrine, and vascular surgery,
and in trial 3 cholecystectomy. Reliability, validity, sensi-
tivity and practicability of the McPeek-Score were inves-
tigated. RESULTS: The score is reliable, because the
results were reproduced in three different hospitals and
by different investigators in one trial. Score points were
distributed over all classes with a maximum of 7–9
points. Validity of the score was demonstrated by corre-
lation to complication rate, ASA-Score, and age with 
correlation coefﬁcients of 0.6–0.7 in the 3 trials: The
score measures what it claims to measure. Sensitivity of
the McPeek-Score was shown in trial 2 by differences
between tumour- and non-tumour patients (8 vs. 7 points,
p < 0.001, chi-square-test) and in trial 3 between emer-
gency- and non-emergency patients (9 vs. 7 points, p <
0.001). The score is very practicable, because the surgeon
needs only a few minutes to get the score value, it does
not interfere with his routine tasks. CONCLUSIONS:
The McPeek-Score is well suited to assess outcome of sur-
gical procedures. It is only applicable to major surgical
situations where mortality and ICU treatment is of 
importance.
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